Alzheimer’s disease has no cure and virtually no palliative treatments are available. Even today its origin is still unknown. All this has driven the international scientific community to back new approaches that allow early diagnosis of the disease and the discovery of a treatment to stop its progression. IRB Barcelona is not oblivious to this tendency. The researchers Patrick Aloy and Natàlia Carulla head projects addressing an alternative slant on the control and progression of the disease and the discovery of new therapeutic agents.
The coordinator of Chemistry and Pharmacology Programme at IRB Barcelona is presented with the Josef Rudinger Memorial Lecture Award during the European Peptide Symposium, in Sofia, Bulgaria.
The award is in recognition of longstanding contributions to the field.
Several media echo on the research lead by Ernest Giralt focused on the use of wasp venom as a strategy to kill cancer cells selectively.
News of the Spanish Scientific News Agency, SINC Agency, on a study perfomed at Ernest Giralt's lab with wasp venom to desing a new therapyagainst breast cancer.
The laboratory of Peptides and Proteins, headed by Ernest Giralt , published in the Journal of Controlled Released a therapy for breast cancer using the wasp venom. The August magazine of “Muy Interesante” has echoed the study.
Around 160 scientists, brought together by IRB Barcelona and the BBVA Foundation in a Barcelona Biomed Conference, are discussing the latest research into one of the hallmarks of Alzheimer’s disease, the amyloid-beta protein that is the major component of the plaques that are characteristic of this debilitating disorder.
According to data from Alzheimer's Disease International in 2013, an estimated 135 million people worldwide will be suffering from dementia in 2050, Alzheimer’s disease being the most prevalent. This condition currently affects over 40 million people but is very strongly age-related, giving rise to the prospect of a ‘21st century plague’ affecting the aging populations across the globe.
A recent report from the Cleveland Clinic published in July 3, indicates that 99.6% of the clinical trials for Alzheimer´s disease have failed, with the result that much of the pharmaceutical industry is discouraged and uncertain as to how to proceed. The scientific community, however, is making substantial progress in understand the underlying causes of the disease, an essential factor in the rational design of innovative therapeutic strategies.
The philologist Maria Blasco, who suffers from Friedreich’s ataxia, has published a book to raise funds for research into this rare and severe hereditary neurodegenerative disease. Written by 17 patients from eight countries, the proceeds from the sale of the novel are devoted to a gene therapy project led by Ernest Giralt, at IRB , and Javier Diaz Nido, at the Severo Ochoa Molecular Biology Centre in Madrid.
Read the news in Diario de notícias.
The media put the spotlight on a paper by Eduardo Soriano published in Nature Communications and involving the participation of IRB researcher Natalia Carulla. The group demonstrates the protective capacity of reelin during the development of Alzheimer's disease in mice.
The study describes the neuroprotective effect of reelin in neurodegenerative diseases.
Co-directed by Eduardo Soriano and Lluís Pujadas, from the University of Barcelona, and the CIBERNED network, the study has involved Bernat Serra-Vidal, Ernest Giralt and Natàlia Carulla, all three scientists at IRB.
“Correo Farmacéutico” gives news about a donation of 200,00 US$ from the North American association FARA for the gene therapy project devoted to Friedreich’s ataxia developed at IRB and CBM Severo Ochoa.
This project has been promoted from various patients’ associations headed by Genefa.
Read the news in “Correo Farmacéutico” (PDF)
28 January 2014